KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Operating Expenses (2016 - 2026)

Emergent BioSolutions has reported Operating Expenses over the past 16 years, most recently at $145.6 million for Q1 2026.

  • For Q1 2026, Operating Expenses fell 15.5% year-over-year to $145.6 million; the TTM value through Mar 2026 reached $616.1 million, down 42.1%, while the annual FY2025 figure was $642.8 million, 44.22% down from the prior year.
  • Operating Expenses for Q1 2026 was $145.6 million at Emergent BioSolutions, down from $176.6 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $630.8 million in Q2 2023 and troughed at $139.3 million in Q2 2025.
  • A 5-year average of $294.3 million and a median of $285.2 million in 2022 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: skyrocketed 100.44% in 2023 and later plummeted 69.6% in 2025.
  • Year by year, Operating Expenses stood at $385.5 million in 2022, then dropped by 16.89% to $320.4 million in 2023, then plummeted by 36.27% to $204.2 million in 2024, then decreased by 13.52% to $176.6 million in 2025, then fell by 17.55% to $145.6 million in 2026.
  • Business Quant data shows Operating Expenses for EBS at $145.6 million in Q1 2026, $176.6 million in Q4 2025, and $154.6 million in Q3 2025.